ES2552338T3 - Compuestos farmacéuticos - Google Patents
Compuestos farmacéuticos Download PDFInfo
- Publication number
- ES2552338T3 ES2552338T3 ES06700879.7T ES06700879T ES2552338T3 ES 2552338 T3 ES2552338 T3 ES 2552338T3 ES 06700879 T ES06700879 T ES 06700879T ES 2552338 T3 ES2552338 T3 ES 2552338T3
- Authority
- ES
- Spain
- Prior art keywords
- retention time
- procedure
- carbocyclic
- groups
- heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64600105P | 2005-01-21 | 2005-01-21 | |
| US64600305P | 2005-01-21 | 2005-01-21 | |
| US64598805P | 2005-01-21 | 2005-01-21 | |
| US64621605P | 2005-01-21 | 2005-01-21 | |
| US64597405P | 2005-01-21 | 2005-01-21 | |
| US646003P | 2005-01-21 | ||
| US646216P | 2005-01-21 | ||
| US646001P | 2005-01-21 | ||
| US645988P | 2005-01-21 | ||
| US645974P | 2005-01-21 | ||
| PCT/GB2006/000210 WO2006077428A1 (en) | 2005-01-21 | 2006-01-20 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2552338T3 true ES2552338T3 (es) | 2015-11-27 |
Family
ID=35967000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06700879.7T Expired - Lifetime ES2552338T3 (es) | 2005-01-21 | 2006-01-20 | Compuestos farmacéuticos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090036435A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1845973B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5475235B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101346886B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006207325B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0606455A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2594477C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2552338T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007008781A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006077428A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| TW200533657A (en) | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| US20080139620A1 (en) * | 2005-01-21 | 2008-06-12 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| EP1845974A1 (en) * | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Pharmaceutical compounds |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| CN101133088B (zh) * | 2005-03-03 | 2011-04-13 | 三菱丽阳株式会社 | 聚合物粒子、含有它的树脂组合物、成型体 |
| SI1901729T1 (sl) * | 2005-05-13 | 2012-05-31 | Topotarget Uk Ltd | Farmacevtske formulacije HDAC inhibitorjev |
| EP1743892A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1743890A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
| US7897589B2 (en) | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| CA2627923C (en) * | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| CA2651152A1 (en) * | 2006-05-05 | 2007-11-15 | Astex Therapeutics Limited | 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer |
| US20090142337A1 (en) * | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
| WO2008007123A2 (en) * | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2049106A2 (en) * | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| CN101868446A (zh) * | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | 某些异羟肟酸化合物的合成方法 |
| EP2070924A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel |
| EP2070925A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel |
| EP2070916A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| AU2008343932B2 (en) | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| WO2009094224A1 (en) | 2008-01-25 | 2009-07-30 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| SI2262493T1 (sl) * | 2008-03-07 | 2015-07-31 | Onxeo Dk Branch Of Onxeo S.A. France | Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata |
| ATE531372T1 (de) | 2008-04-07 | 2011-11-15 | Amgen Inc | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren |
| US9662391B2 (en) | 2008-04-24 | 2017-05-30 | The Invention Science Fund I Llc | Side effect ameliorating combination therapeutic products and systems |
| US9649469B2 (en) | 2008-04-24 | 2017-05-16 | The Invention Science Fund I Llc | Methods and systems for presenting a combination treatment |
| US9282927B2 (en) | 2008-04-24 | 2016-03-15 | Invention Science Fund I, Llc | Methods and systems for modifying bioactive agent use |
| US20090270688A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting a combination treatment |
| US9560967B2 (en) | 2008-04-24 | 2017-02-07 | The Invention Science Fund I Llc | Systems and apparatus for measuring a bioactive agent effect |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| JP2012516329A (ja) | 2009-01-30 | 2012-07-19 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Pi3k阻害剤としてのヘテロアリールおよびその使用 |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| PT2519231T (pt) | 2009-10-01 | 2017-05-25 | Janssen Pharmaceutica Nv | Inibidores do proteassoma para tratamento do cancro |
| EP2603214A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US8859768B2 (en) | 2010-08-11 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MX2013004003A (es) | 2010-10-13 | 2013-10-01 | Millenium Pharmaceuticals Inc | Heteroarilos y usos de los mismos. |
| KR101606250B1 (ko) | 2011-03-23 | 2016-03-24 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
| TW201331194A (zh) * | 2011-12-23 | 2013-08-01 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
| CN103012428A (zh) | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
| EP2951174B1 (en) * | 2013-01-30 | 2017-04-26 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2970135B1 (en) | 2013-03-14 | 2018-07-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP3363434A1 (en) | 2013-03-14 | 2018-08-22 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
| CA2903394C (en) | 2013-03-14 | 2021-08-31 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| JP2016514164A (ja) | 2013-03-14 | 2016-05-19 | エピザイム,インコーポレイティド | アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用 |
| EP2970181B1 (en) | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9394258B2 (en) | 2013-03-14 | 2016-07-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| WO2016044576A1 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor |
| WO2018004290A1 (ko) * | 2016-06-30 | 2018-01-04 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| KR102434226B1 (ko) | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| BR112019003722A2 (pt) | 2016-08-23 | 2019-05-28 | Eisai R&D Man Co Ltd | terapias de combinação para o tratamento de carcinoma hepatocelular |
| WO2018170447A1 (en) | 2017-03-16 | 2018-09-20 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
| IL279367B2 (en) | 2018-06-13 | 2026-05-01 | Novartis Ag | BCMA chimeric antigen receptors and their uses |
| GB201903546D0 (en) * | 2019-03-15 | 2019-05-01 | Ldn Pharma Ltd | Cancer treatment |
| AU2023216263A1 (en) * | 2022-02-04 | 2024-08-22 | Mrja Therapeutics, Inc. | Certain chemical entities, compositions, and methods |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2917432A (en) | 1954-10-05 | 1959-12-15 | Burroughs Wellcome Co | Leukemia treatment |
| US2848455A (en) | 1955-07-18 | 1958-08-19 | Ciba Pharm Prod Inc | Alpha-(p-amino-phenyl)-alpha-lower alkyl glutarimides |
| US2891079A (en) | 1959-01-23 | 1959-06-16 | Searle & Co | 6-methyl-4, 6-pregnadiene-3, 20-dione and 17alpha-acyloxy derivatives thereof |
| US3046301A (en) | 1959-10-29 | 1962-07-24 | Burroughs Wellcome Co | Method of making chlorambucil |
| BE637389A (cg-RX-API-DMAC7.html) | 1962-09-13 | |||
| US3732340A (en) | 1966-07-11 | 1973-05-08 | Asta Werke Ag Chem Fab | N',o-propylene phosphoric acid ester diamides |
| GB1354939A (en) | 1971-10-28 | 1974-06-05 | Ici Ltd | Process for the manufacture of 1,1,2-triphenylalk-1-enes |
| US4005063A (en) | 1973-10-11 | 1977-01-25 | Abbott Laboratories | [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity |
| US3914412A (en) | 1973-10-11 | 1975-10-21 | Abbott Lab | {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity |
| DE2438350C3 (de) | 1974-08-09 | 1979-06-13 | Hoechst Ag, 6000 Frankfurt | Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US4282361A (en) * | 1978-03-16 | 1981-08-04 | Massachusetts Institute Of Technology | Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines |
| DE2845574A1 (de) | 1978-10-19 | 1980-04-24 | Deutsches Krebsforsch | Durch heterocyclische ringe oder alkylreste substituierte analoga von ccnu und verfahren zu deren herstellung |
| DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| OA07174A (fr) | 1981-08-24 | 1984-04-30 | May & Baker Ltd | Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent. |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| DE3372965D1 (en) | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5003011A (en) | 1985-04-09 | 1991-03-26 | The Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4978672A (en) | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| JPS62220196A (ja) | 1986-03-20 | 1987-09-28 | Kyowa Hakko Kogyo Co Ltd | 新規物質ucn―01 |
| IN164232B (cg-RX-API-DMAC7.html) | 1986-04-11 | 1989-02-04 | Hoechst India | |
| NZ224714A (en) | 1987-06-01 | 1990-03-27 | Janssen Pharmaceutica Nv | Substituted benzotriazole derivatives and pharmaceutical compositions |
| GB8714013D0 (en) | 1987-06-16 | 1987-07-22 | Ici Plc | (substituted-aralkyl)heterocyclic compounds |
| EP0308020A3 (en) | 1987-09-18 | 1990-12-05 | Merck & Co. Inc. | 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof |
| US5002755A (en) * | 1988-02-18 | 1991-03-26 | Vanderbilt University | Method of controlling nephrotoxicity of anti-tumor plaintum compounds |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| JPH05507480A (ja) * | 1990-05-26 | 1993-10-28 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 医薬品抵抗性の克服の際に使用するための1,4―ジヒドロピリジン |
| TW295589B (cg-RX-API-DMAC7.html) | 1990-08-30 | 1997-01-11 | Hoechst Ag | |
| GB9112859D0 (en) | 1991-06-14 | 1991-07-31 | Ici Plc | Peptide process |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CA2277954A1 (en) | 1993-11-30 | 1995-06-08 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5502068A (en) * | 1995-01-31 | 1996-03-26 | Synphar Laboratories, Inc. | Cyclopropylpyrroloindole-oligopeptide anticancer agents |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| GB9514380D0 (en) | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| US5675024A (en) | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| WO1997027852A1 (en) * | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU2381397A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| JP4426650B2 (ja) * | 1996-05-03 | 2010-03-03 | アボット・ラボラトリーズ | 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法 |
| DE69728986T2 (de) | 1996-06-21 | 2005-04-07 | Allergan, Inc., Irvine | Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| EP0827742A1 (en) | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| GB9719426D0 (en) | 1997-09-13 | 1997-11-12 | Johnson Matthey Plc | Novel process |
| CN1158269C (zh) | 1997-10-27 | 2004-07-21 | 阿古龙制药公司 | 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物 |
| JP2000186092A (ja) * | 1998-12-22 | 2000-07-04 | Kyowa Hakko Kogyo Co Ltd | Ucn−01の製造法 |
| WO2000038683A1 (en) | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | THROMBIN OR FACTOR Xa INHIBITORS |
| CA2368630A1 (en) | 1999-04-02 | 2000-10-12 | Ruth R. Wexler | Aryl sulfonyls as factor xa inhibitors |
| CA2366932C (en) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| AU781880B2 (en) | 1999-09-17 | 2005-06-16 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| MY125768A (en) | 1999-12-15 | 2006-08-30 | Bristol Myers Squibb Co | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20040087798A1 (en) * | 2000-03-14 | 2004-05-06 | Akira Yamada | Novel amide compounds |
| GB2361236B (en) | 2000-03-29 | 2002-04-24 | Cyclacel Ltd | Pyrimidines useful against proliferative disorders |
| AU2001253540A1 (en) | 2000-04-25 | 2001-11-07 | Bristol-Myers Squibb Company | Use of 5-thio-, sulfinyl- and sulfonylpyrazolo(3,4-b)-pyridines as cyclin dependent kinase inhibitors |
| US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| AU2001212168A1 (en) | 2000-10-20 | 2002-05-06 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides and their use as cyclin dependent kinase (CDK) inhibitors |
| US6455559B1 (en) | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| NZ526624A (en) | 2000-12-22 | 2005-07-29 | Ortho Mcneil Pharm Inc | Substituted triazole diamine derivatives as kinase inhibitors |
| US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| WO2002074298A1 (en) * | 2001-03-21 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Il-6 production inhibitors |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| WO2002092002A2 (en) * | 2001-05-11 | 2002-11-21 | The Burnham Institute | Screening, diagnostic and therapeutic methods relating to riz |
| IL159120A0 (en) | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なピラゾール類似体 |
| WO2003040147A1 (en) | 2001-11-08 | 2003-05-15 | Pharmacia & Upjohn Company | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease__________________________________________________________________________________________________________________________ |
| SE0104462D0 (sv) | 2001-12-29 | 2001-12-29 | Carlbiotech Ltd As | Peptide purifcation (Peptidrening) |
| NZ534069A (en) * | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| MXPA04008577A (es) * | 2002-03-04 | 2005-07-13 | Aton Pharma Inc | Metodos para inducir diferenciacion terminal. |
| US6995168B2 (en) * | 2002-05-31 | 2006-02-07 | Euro-Celtique S.A. | Triazaspiro compounds useful for treating or preventing pain |
| AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| WO2004026867A2 (en) * | 2002-09-19 | 2004-04-01 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
| WO2004039795A2 (en) | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
| US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US7320989B2 (en) * | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| EP1718306A2 (en) * | 2004-02-20 | 2006-11-08 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
| US7842820B2 (en) * | 2004-03-11 | 2010-11-30 | 4Sc Ag | Sulfonylpyrroles |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| EP1845974A1 (en) * | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| WO2006077425A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
| US20080139620A1 (en) * | 2005-01-21 | 2008-06-12 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
-
2006
- 2006-01-20 EP EP06700879.7A patent/EP1845973B1/en not_active Expired - Lifetime
- 2006-01-20 WO PCT/GB2006/000210 patent/WO2006077428A1/en not_active Ceased
- 2006-01-20 US US11/814,461 patent/US20090036435A1/en not_active Abandoned
- 2006-01-20 ES ES06700879.7T patent/ES2552338T3/es not_active Expired - Lifetime
- 2006-01-20 MX MX2007008781A patent/MX2007008781A/es active IP Right Grant
- 2006-01-20 JP JP2007551746A patent/JP5475235B2/ja not_active Expired - Fee Related
- 2006-01-20 CA CA2594477A patent/CA2594477C/en not_active Expired - Fee Related
- 2006-01-20 KR KR1020077018790A patent/KR101346886B1/ko not_active Expired - Fee Related
- 2006-01-20 AU AU2006207325A patent/AU2006207325B2/en not_active Ceased
- 2006-01-20 BR BRPI0606455-8A patent/BRPI0606455A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2594477C (en) | 2016-07-12 |
| WO2006077428A1 (en) | 2006-07-27 |
| EP1845973B1 (en) | 2015-08-12 |
| KR20070107045A (ko) | 2007-11-06 |
| EP1845973A1 (en) | 2007-10-24 |
| AU2006207325B2 (en) | 2012-08-16 |
| US20090036435A1 (en) | 2009-02-05 |
| CA2594477A1 (en) | 2006-07-27 |
| MX2007008781A (es) | 2007-09-11 |
| JP2008528471A (ja) | 2008-07-31 |
| JP5475235B2 (ja) | 2014-04-16 |
| AU2006207325A1 (en) | 2006-07-27 |
| KR101346886B1 (ko) | 2014-01-02 |
| BRPI0606455A (pt) | 2008-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014029454B1 (pt) | Pirrolo [2,3-b] piridinas e métodos para prepará-los | |
| CN105026400A (zh) | 用于制备药物的方法和中间体 | |
| CN1180352A (zh) | 新颖的芳基甘氨酰胺衍生物,其制造方法及含该化合物的药物组合物 | |
| ES2879294T3 (es) | Formas polimórficas de Belinostat y procesos para la preparación de las mismas | |
| HUT70048A (en) | Neurotensine-receptor-active 1-naphtyl-pyrazol-3-carboxamides process for producing them and pharmaceutical compositions containing them as active components | |
| RU2717830C2 (ru) | Способ получения азотсодержащего гетероциклического соединения и его промежуточного соединения | |
| EP3280721B1 (en) | Process for preparation of nitrogen mustard derivatives | |
| CA3103624A1 (en) | Triazine compounds and uses thereof | |
| CA2730071A1 (fr) | Derives anticancereux, leur preparation et leur application en therapeutique | |
| ES2375384T3 (es) | Asimadolina para el tratamiento del síndrome de colon irritable (irritable bowel syndroes). | |
| ES2333628T3 (es) | Procedimiento para preparar derivados de 1-halo-2,7-naftiridinilo. | |
| CN101595090A (zh) | 制备截短侧耳素的方法 | |
| ES2955554T3 (es) | Proceso para producir un derivado de purinona | |
| HUT70557A (en) | N,n'-disubstituted amine derivative, pharmaceutical compositions containing them and process for producing the compounds and the compositions | |
| JP2025001050A (ja) | ガニレリクス又はその塩の製造法 | |
| CN119431379B (zh) | Wrn降解剂及其制备方法和应用 | |
| CN102164947A (zh) | 肽化合物及其制备方法 | |
| EP1487809A1 (en) | Process for the preparation of morpholine derivatives and intermediates therefore | |
| KR101137503B1 (ko) | 고분자 고체 지지체를 이용한 히스티딜-프롤린아미드 유도체의 제조 방법 | |
| WO2002098871A1 (en) | Phenylcarboxamides and process for preparation thereof | |
| CA3214107A1 (en) | New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds | |
| EP1675835B1 (en) | Methods of preparation of dehydro-diketopiperazines in liquid phase or on solid supported phase | |
| WO2021162070A1 (ja) | 核酸製造用モノマーの製造方法 | |
| CA3145287A1 (en) | Process for the preparation of a pyrimidino-diazepine derivative | |
| HK40060361B (en) | Process for the preparation of galnac phosphoramidite epimers |